Acyl-CoA synthetase long-chain family member 4 (ACSL4)
Acyl-CoA synthetase long chain family member 4 (ACSL4) is a long-chain acyl-CoA synthetase that has emerged as an important regulator of lipid metabolism and ferroptosis.
Acyl-CoA synthetase long chain family member 4 (ACSL4) is a long-chain acyl-CoA synthetase that has emerged as an important regulator of lipid metabolism and ferroptosis. In biomedical research, ACSL4 is commonly discussed as a pro-ferroptotic factor because it contributes to the remodeling of membrane phospholipids with polyunsaturated fatty acids, thereby increasing susceptibility to lipid peroxidation. As a result, ACSL4 is frequently studied in cancer biology, metabolic disease, and ischemia-reperfusion injury, where altered ferroptotic signaling can influence cell survival, tissue damage, and treatment response.
Recent studies have placed ACSL4 within broader redox and lipid-metabolic networks involving GPX4, SLC7A11, Nrf2, HO-1, TFR1, and related inflammatory mediators. In these contexts, ACSL4 is not typically treated as a standalone biomarker, but as part of a mechanistic axis that links iron handling, glutathione depletion, oxidative stress, and membrane lipid damage. This makes ACSL4 a recurring target in experimental work on ferroptosis modulation across liver disease, reproductive toxicity, cerebral ischemia, and multiple cancer models.
Where the papers sit
10 papers from the last 6 months study Acyl-CoA synthetase long-chain family member 4 (ACSL4) directly · updated from PubMed 10 Nov 2026
Study type 0 clinical trials · 1 human data · 7 preclinical · 2 unclassified
Themes 3 themes
-
Ferroptosis Across Diseases
Ferroptosis is being treated as a disease-modifiable process, with suppression favored in neurodegeneration, microvascular injury, and bone loss but induction explored against pancreatic cancer. Brain-targeted dual-function PROTACs and Parkin-mediated ACSL4 ubiquitination aim to reduce lipid peroxidation and restore tissue function. Nrf2-dependent protection and Schisandrin B likewise show context-specific control of ferroptotic stress. The central open question is how to inhibit neuronal and vascular damage without weakening ferroptosis-based tumour killing.
4 papers · 40%
-
Ferroptosis in Tissue Injury
Ferroptosis is being linked to ischemic, toxic, and neurodegenerative injury through iron, reactive oxygen species, lipid peroxidation, and glutathione loss. Work on myocardial ischemia-reperfusion and cisplatin-induced acute kidney injury points toward antioxidant and ferroptosis-blocking interventions, including multifunctional polydopamine nanoparticles. Early-onset Alzheimer’s disease studies add computationally nominated ferroptosis genes and druggability rather than a validated therapy. The field is moving from association toward experimental validation, but tissue-specific targets and clinical benefit remain unresolved.
3 papers · 30%
-
Lipid Metabolism in Cancer
Lipid metabolic reprogramming is emerging as a route to lymphatic metastasis and targeted-therapy resistance in cancer. Dual ACSL3/4 inhibition is being used to reshape metabolic and immune microenvironments, while triacsin C-based lipid remodeling is explored to overcome MEK inhibitor resistance. ZDHHC9-driven palmitoylation of ACSL3 links lipid metabolism to cetuximab resistance in colorectal cancer. The recurring direction is toward disrupting ACSL-dependent lipid supply and modification, although the relative roles of ACSL3 and ACSL4 remain context-dependent.
3 papers · 30%
Papers
The 10 papers from the last 6 months that study Acyl-CoA synthetase long-chain family member 4 (ACSL4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Ferroptosis Across Diseases (4)
- Dual-function PROTAC suppresses ferroptosis and restores neuronal function via brain-targeted delivery. Cell chemical biology · 21 Jul 2026 PMID 42480533
- Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Jul 2026 PMID 42439361
- Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer. Oncology reports · 19 Jun 2026 PMID 42318966
- Nuclear Factor Erythroid 2-Related Factor 2-Dependent Ferroptosis Suppression by Salvianolic Acid B Preserves Microvascular Integrity and Reduces Risk Factors for Hemorrhagic Transformation After Cerebral Infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 May 2026 PMID 42186809
Ferroptosis in Tissue Injury (3)
- Integrated bioinformatics analysis, machine learning, and experimental validation reveal that ACSL1 drives myocardial ischemia reperfusion injury via ferroptosis. Journal of bioenergetics and biomembranes · 24 Sept 2026 PMID 42782425
- Neural network-enhanced investigation of ferroptosis and druggability in early-onset alzheimer's disease. Metabolic brain disease · 20 Jul 2026 PMID 42474555
- Multifunctional Polydopamine Nanoparticles to Alleviate Oxidative Stress and Inhibit Ferroptosis for Cisplatin-Induced Acute Kidney Injury Therapy. Molecular pharmaceutics · 11 Jul 2026 PMID 42435348
Lipid Metabolism in Cancer (3)
- A lymph node-targeted nanoplatform reprograms metabolic and immune microenvironments via dual ACSL3/4 inhibition in lymphatic metastatic tumors. Journal of controlled release : official journal of the Controlled Release Society · 1 Oct 2026 PMID 42822540
- ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
- A pH-responsive silver nanoparticle platform overcomes MEK inhibitor resistance in neurofibroma via triacsin C-mediated lipid metabolic reprogramming. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42177691
By study type
Human data, design not indexed (1)
- Neural network-enhanced investigation of ferroptosis and druggability in early-onset alzheimer's disease. Metabolic brain disease · 20 Jul 2026 PMID 42474555
Preclinical: animal, cell and lab studies (7)
- A lymph node-targeted nanoplatform reprograms metabolic and immune microenvironments via dual ACSL3/4 inhibition in lymphatic metastatic tumors. Journal of controlled release : official journal of the Controlled Release Society · 1 Oct 2026 PMID 42822540
- ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
- Integrated bioinformatics analysis, machine learning, and experimental validation reveal that ACSL1 drives myocardial ischemia reperfusion injury via ferroptosis. Journal of bioenergetics and biomembranes · 24 Sept 2026 PMID 42782425
- Multifunctional Polydopamine Nanoparticles to Alleviate Oxidative Stress and Inhibit Ferroptosis for Cisplatin-Induced Acute Kidney Injury Therapy. Molecular pharmaceutics · 11 Jul 2026 PMID 42435348
- Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer. Oncology reports · 19 Jun 2026 PMID 42318966
- Nuclear Factor Erythroid 2-Related Factor 2-Dependent Ferroptosis Suppression by Salvianolic Acid B Preserves Microvascular Integrity and Reduces Risk Factors for Hemorrhagic Transformation After Cerebral Infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 May 2026 PMID 42186809
- A pH-responsive silver nanoparticle platform overcomes MEK inhibitor resistance in neurofibroma via triacsin C-mediated lipid metabolic reprogramming. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42177691
Unclassified: not yet indexed with MeSH (2)
- Dual-function PROTAC suppresses ferroptosis and restores neuronal function via brain-targeted delivery. Cell chemical biology · 21 Jul 2026 PMID 42480533
- Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Jul 2026 PMID 42439361
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.